






Original Article

Trends in facility-level rates of *Clostridioides difficile* infections in US hospitals, 2019–2020

Ashley N. Rose MPH , James Baggs PhD , Sophia V. Kazakova MD, PhD, MPH , Alice Y. Guh MD, MPH, Sarah H. Yi PhD , Natalie L. McCarthy MPH, John A. Jernigan MD, MS and Sujan C. Reddy MD, MSc 

Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

Abstract

Objectives: The coronavirus disease 2019 pandemic caused substantial changes to healthcare delivery and antibiotic prescribing beginning in March 2020. To assess pandemic impact on *Clostridioides difficile* infection (CDI) rates, we described patients and trends in facility-level incidence, testing rates, and percent positivity during 2019–2020 in a large cohort of US hospitals.

Methods: We estimated and compared rates of community-onset CDI (CO-CDI) per 10,000 discharges, hospital-onset CDI (HO-CDI) per 10,000 patient days, and *C. difficile* testing rates per 10,000 discharges in 2019 and 2020. We calculated percent positivity as the number of inpatients diagnosed with CDI over the total number of discharges with a test for *C. difficile*. We used an interrupted time series (ITS) design with negative binomial and logistic regression models to describe level and trend changes in rates and percent positivity before and after March 2020.

Results: In pairwise comparisons, overall CO-CDI rates decreased from 20.0 to 15.8 between 2019 and 2020 ($P < .0001$). HO-CDI rates did not change. Using ITS, we detected decreasing monthly trends in CO-CDI (-1% per month, $P = .0036$) and HO-CDI incidence (-1% per month, $P < .0001$) during the baseline period, prior to the COVID-19 pandemic declaration. We detected no change in monthly trends for CO-CDI or HO-CDI incidence or percent positivity after March 2020 compared with the baseline period.

Conclusions: While there was a slight downward trajectory in CDI trends prior to March 2020, no significant change in CDI trends occurred during the COVID-19 pandemic despite changes in infection control practices, antibiotic use, and healthcare delivery.

(Received 7 December 2021; accepted 24 February 2022; electronically published 19 May 2022)

Clostridioides difficile is the most common pathogen causing healthcare-associated infections (HAIs) in the United States.¹ Frequent and inappropriate antibiotic use drives increases in *Clostridioides difficile* infection (CDI).^{1–3} Due to reported changes in both inpatient and outpatient antibiotic use during 2020, we assessed trends in community-onset CDI (CO-CDI) and hospital-onset CDI (HO-CDI).^{4,5} In addition, we have described inpatients diagnosed with CDI, facility-level testing rates, and percent positivity during 2020 compared with 2019 in a large cohort of US hospitals. We used an interrupted time series (ITS) design to assess whether changes in CDI trends corresponded with changes in healthcare delivery starting in March 2020 when the COVID-19 pandemic began in the United States.^{6–9}

Methods

We conducted a retrospective cohort study using adult and pediatric inpatient records from hospitals included in the Premier Healthcare Database, Special Release (PHD-SR) (May 31, 2021)

Author for correspondence: Ashley N. Rose, E-mail: OUM0@cdc.gov

Cite this article: Rose AN, et al. (2023). Trends in facility-level rates of *Clostridioides difficile* infections in US hospitals, 2019–2020. *Infection Control & Hospital Epidemiology*, 44: 238–245, <https://doi.org/10.1017/ice.2022.69>

from January 1, 2019–December 31, 2020. The PHD-SR contains records for all inpatients discharged from participating acute care, general, nonfederal US hospitals.¹⁰ Inpatient discharge records included diagnostic and procedure codes, demographic information, admission and discharge dates, and facility characteristics. Inpatient billing records were used to identify tests and treatment. Hospitals in our cohort reported at least 1 inpatient discharge and patient day (PD) each month from January 2019–December 2020 and hospitals with incomplete reporting of inpatient discharges, PDs, or *C. difficile* testing (based on billing records) were excluded.

Within the hospital cohort, we identified inpatients diagnosed with CDI, which we defined as hospitalizations with an *International Classification of Diseases, Tenth Revision, Clinical Modification* (ICD-10-CM) primary or secondary diagnosis code indicating enterocolitis due to *Clostridioides difficile* (A04.71 or A04.72) and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) during January 2019–December 2020.^{2,3} For this cohort, we described demographic characteristics and CDI antibiotic therapy stratified by epidemiology classification (community-onset, hospital-onset) and year. Nonincident CDI, defined as inpatients with an admission in the same facility within the previous 30 days, were excluded.

CO-CDI hospitalizations were defined as those with a CDI diagnosis code in the primary diagnostic position and inpatient treatment initiated any time during the hospitalization. HO-CDI hospitalizations were defined as those with a CDI diagnosis code in any secondary diagnostic position and inpatient treatment initiated after admission on hospital day 4 or later.^{2,3}

We also described facility-level *C. difficile* testing rates among our cohort of hospitals. Use of nucleic acid amplification testing (NAAT) was assessed using inpatient charges for *C. difficile* tests, and each test was categorized as NAAT if its description contained the term “NAAT,” “PCR,” “amplified,” or “DNA.” All other tests for *C. difficile* were categorized as “non-NAAT.”³ For inpatients who were tested more than once for *C. difficile*, we included their first *C. difficile* test during the hospitalization. Testing for *C. difficile* was categorized based on the hospital day on which the test was obtained (tests obtained prior to hospital day 4 or on hospital day 4 or later).

We estimated monthly incidence rates of CO-CDI per 10,000 discharges, HO-CDI per 10,000 PD, and *C. difficile* testing rates per 10,000 discharges by facility from January–December of 2019 and 2020 and compared monthly differences of the rates of CDI, *C. difficile* testing, and percent positivity between years. Median differences in the rates of CDI, *C. difficile* testing, and percent positivity were calculated for each month, and the Wilcoxon signed-rank test was used to evaluate statistical significance; $P < .01$ was considered significant.

Using ITS, we conducted segmented regression analyses using multivariable generalized estimating equation (GEE) negative binomial models to describe level and trend changes in CO-CDI and HO-CDI rates before and after the COVID-19 pandemic began in March 2020. In the models we included a monthly trend parameter, an indicator for the period after March 2020, and an interaction term between the trend and indicator parameters.^{11,12} The models estimated effects for a baseline rate of trend from the monthly trend parameter, a level change in the rate in March 2020 from the indicator parameter, and the change in the rate between the baseline and follow-up periods from the interaction term. The models adjust for patient population and hospital characteristics. Collinearity and confounding were assessed for patient and hospital characteristics to develop final models for each outcome. The modeled outcome for the CO-CDI model was the number of events, offset by the natural log of the number of discharges. The CO-CDI model was adjusted for calendar month, the percentage of patients aged ≥ 65 years, the percentage of patients admitted from skilled nursing facilities, percentage of patients of Hispanic ethnicity, the percentage of patients of White race, the percentage of patients of Black race, mean hospital length of stay, the patient case-mix index (not including births), and the NAAT use category based on the proportion of NAAT tests used in each hospital month. Categories of NAAT use were defined based on tertiles of the proportion of NAAT test use as follows: no/low use (hospital months with 0.0%–4.8%), intermediate use (hospital months with $>4.8\%$ and $<100.0\%$ NAAT test use), and NAAT use only (hospital months with 100.0% NAAT test use). For the HO-CDI model, the modeled outcome was the number of events, offset by the natural log of the number of patient days. The HO-CDI model was adjusted for percentage of patients aged 50–64 years, percentage of patients admitted from skilled nursing facilities, mean hospital length of stay, hospital bed size category, US Census division, CO-CDI rate, and NAAT use category.

We used logistic regression events/trials models with an ITS design to assess level and trend changes in the proportion

of positive tests for *C. difficile* before and after March 2020 stratified by day a test was obtained (before hospital day 4 and hospital day 4 or later). *Clostridioides difficile* testing results were not available in the data source, but one can infer that hospitalized inpatients receive treatment for CDI based on a positive test result. Thus, we calculated percent positivity as the number of inpatients diagnosed with CDI over the total number of discharges with a test for *C. difficile*. The logistic model for the proportion of positive tests for *C. difficile* obtained prior to hospital day 4 was adjusted for month, the percentage of patients aged ≥ 65 years, the percentage of patients aged 50–64 years, the percentage of patients of male sex, the percentage of patients of Hispanic ethnicity, case mix index (not including births), hospital teaching status, and NAAT use category. The logistic model for the proportion of positive tests for *C. difficile* obtained on hospital day 4 or later was adjusted for month, case-mix index (not including births), and CO-CDI rate.

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See eg, 45 CFR part 46; 21 CFR part 56; 42 USC §241(d), 5 USC §552a, 44 USC §3501 et seq.). All data were analyzed using PySpark software (Python) on the Data Collation and Integration for Public Health Event Response (DCIPHER) platform and SAS version 9.4 software (SAS Institute, Cary, NC). Due to the number of hypothesis tests and to guard against type 1 error, we set α at 0.01.

Results

Among 775 hospitals included in our analysis, most were nonteaching (72.5%) and located in urban settings (67.9%), with 0–99 beds as the most common bed size category (31.6%) and 749 (96.6%) reporting at least 1 inpatient with CDI during the study period (Table 1). We identified 47,658 inpatients diagnosed with CDI during January 2019–December 2020. CO-CDI represented 55.0% of all incident CDI (Table 2). In 2019, a total of 26,450 inpatients with CDI were identified in our hospital cohort with a rate of 34.7 per 10,000 discharges compared with 21,208 inpatients with CDI identified in 2020 with an overall rate of 30.5 per 10,000 discharges (Table 1). The rate of CO-CDI per 10,000 discharges was 20.0 in 2019 compared with 15.8 in 2020 ($P < .0001$) (Table 1 and Supplementary Appendix Table S1 online). Rates of HO-CDI per 10,000 PD were similar between years: 3.3 in 2019 compared with 3.2 in 2020 ($P = .0163$).

Most inpatients diagnosed with CDI in our study were female (range, 51.5%–64.3%) and aged 65 years or older (range, 58.6%–60.6%) (Table 2). The mortality rate was higher among inpatients with HO-CDI compared with those diagnosed with CO-CDI in both 2019 (8.7% vs 1.2%, respectively) and 2020 (10.7% vs 1.2%, respectively). The mean length of stay (LOS) of inpatients with CO-CDI was 5.5 days in both 2019 and 2020. Inpatients with HO-CDI had a mean LOS of 18.7 days in 2019 and 19.2 days in 2020. Most CO-CDI in both years occurred in a nonteaching hospital, whereas most HO-CDI occurred in teaching hospitals. A higher proportion of inpatients with HO-CDI were from hospitals with ≥ 500 beds in 2019 and 2020 (41.1% and 38.7%, respectively) compared with CO-CDI (27.7% and 26.9%, respectively).

Among inpatients diagnosed with CO-CDI and HO-CDI in 2019 and 2020, vancomycin was the most commonly used medication during hospitalization (range, 86.9%–90.6%), followed by metronidazole (range, 35.0%–53.5%) and fidaxomicin (range, 4.4%–8.9%) (Table 2). The proportion of inpatients with CDI

Table 1. Characteristics and CDI Rates Among Hospital Cohort

Variable	Total Hospitals (N = 775) ^a	
	No.	%
Hospital type		
Urban ^b	526	67.9
Rural ^b	249	32.1
Teaching	213	27.5
Nonteaching	562	72.5
Hospital size		
0–99 beds	245	31.6
100–199 beds	170	21.9
200–299 beds	128	16.5
300–399 beds	96	12.4
400–499 beds	48	6.2
≥500 beds	88	11.4
US Census division		
South Atlantic (DC, DE, FL, GA, MD, NC, SC, VA, WV)	176	22.7
Northeast Central (IL, IN, MI, OH, WI)	161	20.8
Southwest Central (AR, LA, OK, TX)	94	12.1
Mid-Atlantic (NJ, NY, PA)	79	10.2
Pacific (AK, CA, HI, OR, WA)	77	9.9
Southeast Central (AL, KY, MS, TN)	70	9.0
Northwest Central (IA, KS, MN, MO, ND, NE, SD)	63	8.1
Mountain (AZ, CO, ID, MT, NM, NV, UT, WY)	42	5.4
New England (CT, MA, ME, NH, RI, VT)	13	1.7
Inpatients diagnosed with CDI, No.		
All	47,658	
2019	26,450	
2020	21,208	
C. difficile tests, No.		
All	509,033	
2019	274,041	
2020	234,992	
2019		
Overall CDI rate, per 10,000 discharges ^c	34.7	
CO-CDI rate, per 10,000 discharges ^{c,d}	20.0	
HO-CDI rate, per 10,000 PDs ^{e,f}	3.3	
Rate of <i>C. difficile</i> tests before hospital day 4, per 10,000 discharges ^c	239.6	
Rate of <i>C. difficile</i> tests on hospital day 4 or later, per 10,000 discharges ^c	119.4	
2020		
Overall CDI rate, per 10,000 discharges ^c	30.5	
CO-CDI rate, per 10,000 discharges ^{c,d}	15.8	
HO-CDI rate, per 10,000 PD ^{e,f}	3.2	
Rate of <i>C. difficile</i> tests before hospital day 4, per 10,000 discharges ^c	214.8	
Rate of <i>C. difficile</i> tests on hospital day 4 or later, per 10,000 discharges ^c	122.8	

Note. CDI, *Clostridioides difficile* infection; CO-CDI, community-onset CDI; HO-CDI, hospital-onset CDI.

^aOf 775 hospitals included in our analysis, 749 (96.6%) reported at least 1 CDI case during the study period; 692 reported pediatric data (89.3%) and 3 were children's hospitals (0.4%).

^bThe PHD-SR defines urban settings as areas whose core census blocks have a population density of at least 1,000 people per square mile, and surrounding census blocks have an overall density of at least 500 people per square mile; areas that did not meet this definition were considered rural.²⁵

^cRate per 10,000 discharges.

^dInpatients diagnosed with CO-CDI were defined as those with an ICD-10-CM diagnosis code of A04.71 or A04.72 in the primary diagnostic position and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) initiated during the hospitalization.

^eRate per 10,000 patient days.

^fInpatients diagnosed with HO-CDI were defined as those with an A04.71 or A04.72 ICD-10-CM diagnosis code in any secondary diagnostic position and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) initiated after admission on hospital day 4 or later.

Table 2. Inpatients Diagnosed with CDI by Epidemiology Classification and Year, 2019–2020

Variable	Overall CDI (N = 47,658)							
	CO-CDI (N = 26,230, 55.0%) ^a				HO-CDI (N = 21,428, 45.0%) ^b			
	2019 (N = 15,233, 58.1%)		2020 (N = 10,997, 41.9%)		2019 (N = 11,217, 52.3%)		2020 (N = 10,211, 47.7%)	
Patient characteristics	No.	%	No.	%	No.	%	No.	%
Sex								
Female	9,793	64.3	7,014	63.8	5,935	52.9	5,261	51.5
Male	5,437	35.7	3,977	36.2	5,282	47.1	4,947	48.4
Unknown	3	0.02	6	0.1	0	0.0	3	0.03
Age, median y (IQR)	70.0	(57.0–80.0)	69.0	(57.0–80.0)	68.0	(57.0–78.0)	68.0	(57.0–77.0)
Age, mean y	66.2		66.1		65.4		65.6	
Age group								
0–17 y	230	1.5	149	1.4	171	1.5	135	1.3
18–49 y	2,306	15.1	1,649	15.0	1,548	13.8	1,388	13.6
50–64 y	3,469	22.8	2,530	23.0	2,887	25.7	2,704	26.5
≥65 y	9,228	60.6	6,669	60.6	6,611	58.9	5,984	58.6
Race								
White	12,534	82.3	8,925	81.2	8,342	74.4	7,516	73.6
Black	1,439	9.4	1,180	10.7	1,671	14.9	1,542	15.1
Asian	164	1.1	125	1.1	160	1.4	198	1.9
Other	847	5.6	581	5.3	831	7.4	706	6.9
Unknown	249	1.6	186	1.7	213	1.9	249	2.4
Ethnicity								
Hispanic	1,066	7.0	743	6.8	878	7.8	845	8.3
Non-Hispanic	11,711	76.9	8,600	78.2	8,160	72.7	7,500	73.5
Unknown	2,456	16.1	1,654	15.0	2,179	19.4	1,866	18.3
Admission source								
Nonhealthcare facility point of origin	12,968	85.1	9,507	86.5	8,529	76.0	7,747	75.9
Clinic	1,025	6.7	663	6.0	766	6.8	686	6.7
Transfer from a different hospital	632	4.1	423	3.8	1,243	11.1	1,110	10.9
Transfer from SNF, ICF, or born inside hospital	319	2.1	208	1.9	379	3.4	375	3.7
Transfer from health facility or born outside hospital	125	0.8	94	0.9	168	1.5	165	1.6
Discharge status								
Discharged to home or self-care	8,913	58.5	6,410	58.3	2,701	24.1	2,329	22.8
Discharged/Transferred to SNF, ICF, or other facility	2,757	18.1	1,695	15.4	3,708	33.1	2,968	29.1
Discharged to home health organization	2,572	16.9	2,049	18.6	1,829	16.3	1,904	18.6
Died	184	1.2	136	1.2	978	8.7	1,089	10.7
LOS, median d (IQR)	4.0	(3.0–6.0)	4.0	(3.0–7.0)	13.0	(8.0–22.0)	14.0	(9.0–23.0)
LOS, mean d	5.5		5.5		18.7		19.2	
CDI treatment^c								
Vancomycin	13,244	86.9	9,814	89.2	9,866	88.0	9,256	90.6
Metronidazole	8,146	53.5	5,473	49.8	4,354	38.8	3,570	35.0
Fidaxomicin	1,311	8.6	980	8.9	515	4.6	445	4.4
Metronidazole only	1,496	9.8	844	7.7	1,149	10.2	805	7.9
First day of CDI treatment, median (IQR)	1.0	(1.0–2.0)	1.0	(1.0–2.0)	7.0	(5.0–11.0)	7.0	(5.0–11.0)
First day of CDI treatment, mean	1.3		1.4		9.6		9.9	
Inpatient CDI therapy, median DOT (IQR) ^d	5.0	(3.0–8.0)	5.0	(3.0–8.0)	6.0	(3.0–12.0)	7.0	(3.0–12.0)
Inpatient CDI therapy, mean DOT	6.7		6.8		9.2		9.5	

(Continued)

Table 2. (Continued)

Variable	Overall CDI (N = 47,658)							
	CO-CDI (N = 26,230, 55.0%) ^a				HO-CDI (N = 21,428, 45.0%) ^b			
	2019 (N = 15,233, 58.1%)		2020 (N = 10,997, 41.9%)		2019 (N = 11,217, 52.3%)		2020 (N = 10,211, 47.7%)	
Patient characteristics	No.	%	No.	%	No.	%	No.	%
Hospital characteristics								
Urban	12,962	85.1	9,378	85.3	9,988	89.0	9,146	89.6
Rural	2,271	14.9	1,619	14.7	1,229	11.0	1,065	10.4
Teaching	6,109	40.1	4,569	41.5	6,095	54.3	5,495	53.8
Nonteaching	9,124	59.9	6,428	58.5	5,122	45.7	4,716	46.2
Hospital size								
0–99 beds	1,231	8.1	896	8.1	425	3.8	416	4.1
100–199 beds	2,409	15.8	1,837	16.7	1,219	10.9	1,169	11.4
200–299 beds	2,807	18.4	1,992	18.1	1,600	14.3	1,557	15.2
300–399 beds	2,844	18.7	2,039	18.5	2,085	18.6	1,976	19.4
400–499 beds	1,724	11.3	1,275	11.6	1,275	11.4	1,137	11.1
≥500 beds	4,218	27.7	2,958	26.9	4,613	41.1	3,956	38.7
US Census division								
South Atlantic	4,364	28.6	3,208	29.2	2,911	26.0	2,689	26.3
Northeast Central	2,919	19.2	2,104	19.1	2,203	19.6	1,932	18.9
Southwest Central	1,630	10.7	1,120	10.2	1,247	11.1	1,067	10.4
Mid-Atlantic	1,879	12.3	1,379	12.5	1,704	15.2	1,477	14.5
Pacific	1,115	7.3	695	6.3	698	6.2	671	6.6
Southeast Central	1,211	7.9	828	7.5	797	7.1	719	7.0
Northwest Central	837	5.5	604	5.5	580	5.2	541	5.3
Mountain	932	6.1	822	7.5	859	7.7	905	8.9
New England	346	2.3	237	2.2	218	1.9	210	2.1

Note. CDI, *Clostridioides difficile* infection; CO-CDI, community-onset CDI; HO-CDI, hospital-onset CDI; SNF, skilled nursing facility; ICF, intermediate care facility; IQR, interquartile range; LOS, length of stay; DOT, days of therapy.

^aInpatients diagnosed with CO-CDI were defined as those with an ICD-10-CM diagnosis code of A04.71 or A04.72 in the primary diagnostic position and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) initiated during the hospitalization.

^bInpatients diagnosed with HO-CDI were defined as those with an A04.71 or A04.72 ICD-10-CM diagnosis code in any secondary diagnostic position and inpatient treatment with metronidazole (parenteral or oral), fidaxomicin, or vancomycin (oral) initiated after admission on hospital day 4 or later.

^cPatients may have received >1 medication during their hospitalization and therefore percentages may be >100% when summed.

^d1 DOT represents the use of a single antibiotic on a given day regardless of the no. of doses or dosage strength.

who received metronidazole or fidaxomicin was higher among CO-CDI cases (49.8%–53.5%, 8.6%–8.9%, respectively) compared with HO-CDI cases (35.0%–38.8%, 4.4%–4.6%, respectively) in both years. The mean first day of treatment following admission among inpatients with CO-CDI was 1.3 days in 2019 and 1.4 days in 2020. Among inpatients with HO-CDI, the mean first day of treatment following admission was 9.6 days in 2019 and 9.9 days in 2020.

We identified 274,041 tests for *C. difficile* in 2019 and 234,992 in 2020 (Table 1). The overall rate of *C. difficile* testing obtained prior to hospital day 4 in 2019 was 239.6 per 10,000 discharges compared with the 2020 rate of 214.8 per 10,000 discharges ($P < .0001$) (Supplementary Appendix Table S1 online). In 2019, the overall rate of *C. difficile* testing obtained on hospital day 4 or later was 119.4 per 10,000 discharges and 122.8 per 10,000 discharges in 2020 ($P < .0001$).

Pairwise comparisons between 2019 and 2020 showed significantly lower total and monthly median CO-CDI rates in

March–December (Fig. 1 and Supplementary Appendix Table S1 online). Total and all monthly *C. difficile* testing rates for tests obtained before hospital day 4 were significantly lower in 2020 than in 2019. We also observed a decline in total and monthly median CO-CDI percent positivity in 2020 compared to 2019 ($P < .0001$) (Supplementary Appendix Table S2 online).

Pairwise comparisons of total and monthly median HO-CDI rates per 10,000 PDs did not show significant differences between 2019 and 2020 ($P = .0163$) (Fig. 1, Supplementary Appendix Table S1 online). During January–February, median *C. difficile* testing rates for tests obtained on hospital day 4 or later were lower in 2020 than in 2019. However, for the entire year, *C. difficile* testing rates for tests obtained on hospital day 4 or later were significantly higher in 2020 than in 2019 ($P < .0001$), with significant increases during April and August–December. HO-CDI percent positivity did not change in 2020 compared with 2019 ($P = .3156$) (Supplementary Appendix Table S2 online).

Table 3. Changes in CO-CDI and HO-CDI Incidence and Percent Positivity Among 775 Adult and Pediatric Acute-Care Hospitals, 2019–2020

	CO-CDI					
	CO-CDI Incidence (26,230 Cases and 14,594,274 Discharges) ^{a,b}			% Positivity of <i>C. difficile</i> Tests Obtained on Hospital Day <4 (26,230 Cases and 332,406 tests) ^c		
	Estimate	99% CI	P Value	Estimate	99% CI	P Value
Baseline monthly trend	0.99	(0.99–1.00)	.0036	1.00	(0.99–1.01)	.8701
Level change around March 2020	0.97	(0.87–1.08)	.5021	0.95	(0.84–1.08)	.3092
Trend change	0.99	(0.97–1.00)	.0433	0.99	(0.97–1.00)	.0419
Monthly trend after March 2020	0.98	(0.97–1.00)	.0015	0.99	(0.97–1.00)	.0469
	HO-CDI					
	HO-CDI Incidence (N = 21,428 Cases and 14,594,274 Discharges) ^{d,e}			% Positivity of <i>C. difficile</i> Tests Obtained on Hospital Day ≥ 4 (N = 21,428 Cases and N = 176,627 Tests) ^f		
	Estimate	99% CI	P Value	Estimate	99% CI	P Value
Baseline monthly trend	0.99	(0.98–0.99)	<.0001	1.00	(0.99–1.01)	.7879
Level change around March 2020	1.11	(0.98–1.25)	.0314	0.92	(0.81–1.05)	.1076
Trend change	1.01	(0.99–1.02)	.2509	1.01	(0.99–1.02)	.1540
Trend after March 2020	0.99	(0.98–1.01)	.2851	1.01	(0.99–1.03)	.1526

Note. CO-CDI, community-onset *Clostridioides difficile* infection; HO-CDI, hospital-onset *Clostridioides difficile* infection; CI, confidence interval.
^aNegative binomial regression; modeled outcome was the number of events, offset by the natural log of the number of discharges.
^bAdjusted for month, % of patients aged ≥ 65 years, % of patients admitted from skilled nursing facilities, % of patients of Hispanic ethnicity, % of patients of White race, % of patients of Black race, mean hospital length of stay, patient case-mix index (no births), and NAAT use category.
^cLogistic regression model adjusted for month, % of patients aged ≥65 years, % of patients aged 50–64 years, % of patients of male sex, % of patients of Hispanic ethnicity, patient case-mix index (no births), hospital teaching status, and NAAT use category.
^dModeled outcome was the number of events, offset by the natural log of the no. of patient days.
^eAdjusted for month, % of patients aged ≥65 years, % of patients aged 50–64 years, % of patients admitted from skilled nursing facilities, mean hospital length of stay, hospital bed size category, hospital US Census division, CO-CDI rate, and NAAT use category.
^fAdjusted for month, patient case-mix index (no births), and CO-CDI rate.




Fig. 1. Pairwise differences in total and monthly facility-level CO-CDI and HO-CDI rates, January 2019–December 2020. *Indicates a statistically significant facility-level median difference in rates at $P < .01$.

In the ITS design, decreasing monthly trends were observed in CO-CDI (-1% per month, $P = .0036$) and HO-CDI incidence (-1% per month; $P < .0001$) during the baseline period prior to the COVID-19 pandemic declaration (Table 3 and Supplementary Appendix Figs. S1 and S2 online). There was no change in trend for either measure after March 2020 (Table 3) and there were no changes in monthly trends or level shifts in CO-CDI or HO-CDI percent positivity during the study period.

Discussion

Our findings suggest that despite changes in US healthcare utilization during the pandemic, there were no substantial changes in the incidence of CO-CDI and HO-CDI. In total and monthly pairwise comparisons, we detected a decrease in CO-CDI rates in 2020 compared with 2019. Segmented regression revealed decreasing CO-CDI trends prior to the pandemic, which continued after the pandemic declaration. Pairwise comparisons revealed no difference in HO-CDI incidence between 2020 and 2019. Similar to CO-CDI, though, segmented regression of HO-CDI rates revealed a decreasing trend that was present prior to the pandemic. However, this trend did not change significantly after March 2020. We further observed changes in *C. difficile* testing comparing 2020 to 2019.

Healthcare utilization in the United States during the COVID-19 pandemic underwent substantial changes, including a decrease in outpatient care-seeking and therefore less outpatient antibiotic use.^{5,7,8} Hospital-wide inpatient antibiotic use as well as use of vancomycin and levofloxacin reportedly declined between

2019 and 2020; however, the use of certain agents including azithromycin and ceftriaxone increased between years.⁴ Patients were less likely to present to the emergency department (ED) and hospital admissions substantially decreased, particularly during early months of the pandemic.^{6,9} A recent study comparing average outpatient antibiotic prescriptions during 2017–2019 with 2020 reported an estimated decline of 4%–9% in January–March 2020, with larger decreases in April and May 2020 (39% and 42%, respectively).⁵ Despite reports of decreased overall outpatient antibiotic use and lower-than-predicted hospital admissions during the pandemic year, we did not detect significant changes in CO-CDI and HO-CDI rates or CO-CDI and HO-CDI percent positivity trends after the pandemic began.^{4,9,13} We did, however, detect a continuation of the decreasing trend in CO-CDI rates after March 2020, which may have been influenced by these factors. Given changes in inpatient antibiotic use and healthcare utilization, the unchanged rate of HO-CDI may suggest that other factors are contributing to HO-CDI rates, such as potential changes in susceptibility of admitted patients or decreased adherence to environmental cleaning and infection prevention, particularly during non-COVID-19 patient care. Further analyses of CDI rates, including postdischarge CDI rates, throughout the different phases of the pandemic may bring insights to the drivers of hospital-associated CDI.

Although the COVID-19 pandemic led to recommendations for enhanced infection control measures including personal protective equipment use in US hospitals, many hospitals faced the challenge of inadequate PPE stock due to supply chain shortages.¹⁴ Despite these challenges, we did not observe a change in HO-CDI incidence after the pandemic began.^{15,16} A recent study of 148 HCA healthcare-affiliated hospitals nationwide reported that HO-CDI rates were stable during the COVID-19 pandemic and were not significantly associated with COVID-19 burden.¹⁷ Another study estimating national healthcare-associated infection (HAI) standardized infection ratios (SIRs) using data from the National Healthcare Safety Network (NHSN) showed decreases in SIRs for HO-CDI laboratory-identified (LabID) events in 2020 compared with 2019 across all quarters; however, the difference decreased from quarter 1 (–17.5%) to quarter 4 (–5.5%).¹⁸ Consistent with our observed HO-CDI trends before the pandemic, HO-CDI LabID event national SIRs steadily decreased from 0.63 in quarter 1 to 0.55 in quarter 4 of 2019. In 2020, the SIR remained stable at 0.52 across all quarters.¹⁸

In pairwise comparisons, testing rates for *C. difficile* changed significantly overall between 2019 and 2020. Total and monthly rates of *C. difficile* testing obtained prior to hospital day 4 decreased in all comparisons. Although rates of *C. difficile* testing obtained on hospital day 4 or later also decreased in January and February 2020, these rates then increased during five of the eight months between April and December 2020. These changes in testing do not appear to be inappropriate as we did not observe a change in percent positivity trends for *C. difficile* tests in the ITS study. Frequency of testing is important when interpreting trend results, particularly for CDI. Diagnostic stewardship of *C. difficile* testing has become increasingly important as clinicians attempt to optimize NAAT testing to reduce inappropriate diagnoses, unnecessary treatment, and facility HAI rates.^{19,20} Trends in *C. difficile* testing should be monitored because focus on diagnostic stewardship for *C. difficile* testing has increased. Further study is needed to assess appropriateness of *C. difficile* testing during the COVID-19 pandemic.

In 2018, the Infectious Diseases Society of America (IDSA) released guidelines for CDI treatment, recommending use of

vancomycin or fidaxomicin over metronidazole alone.²¹ In our study, <10% of all inpatients diagnosed with CDI between 2019 and 2020 were treated with metronidazole only. These inpatients were included in our study because IDSA recommendations to remove metronidazole as a first-line treatment may take time to be adopted in practice.

Our study may have been limited by the use of discharge codes to identify inpatients diagnosed with CDI because such data are mainly used for billing purposes; therefore, misclassification of the outcome is possible. We supplemented discharge codes with treatment data to increase the specificity of our case definition, and we applied a previously used definition for CDI.^{2,3} However, misclassification in case or treatment data may still exist.²² Our findings are also consistent with previously reported CDI estimates from the 2019 National and State Healthcare-Associated Infections Progress Report.²³ The size of our study was a strength, unlike recent single-center and small multicenter studies of CDI rates during the COVID-19 pandemic period, our study includes 2 years of data from a consistent cohort of 775 hospitals nationwide.^{15,24}

Although infection control practices, antibiotic use, and healthcare delivery changed during the COVID-19 pandemic, we did not observe a strong influence on preceding downward trends in annual CDI rates across a large cohort of US hospitals. Given the significant morbidity and mortality associated with CDI and the burden in US hospitals, ongoing monitoring of the trends in CDI as healthcare delivery returns to prepandemic levels is important to inform hospital antibiotic stewardship and infection control programs.¹

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/ice.2022.69>

Acknowledgments. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Financial support. This work was funded through salary funds at the Centers for Disease Control and Prevention. The authors received no other outside funds.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

- Magill SS, O'Leary E, Janelle SJ, *et al.* Changes in prevalence of healthcare-associated infections in US hospitals. *N Engl J Med* 2018;379: 1732–1744.
- Kazakova SV, Baggs J, McDonald LC, *et al.* Association between antibiotic use and hospital-onset *Clostridioides difficile* infection in US acute-care hospitals, 2006–2012: an ecologic analysis. *Clin Infect Dis* 2020;70:11–18.
- Kazakova SV, Baggs J, Yi SH, *et al.* Associations of facility-level antibiotic use and hospital-onset *Clostridioides difficile* infection in US acute-care hospitals, 2012–2018. *Infect Control Hosp Epidemiol* 2021. doi: [10.1017/ice.2021.151](https://doi.org/10.1017/ice.2021.151).
- Rose AN, Baggs J, Wolford H, *et al.* Trends in antibiotic use in US hospitals during the coronavirus disease 2019 pandemic. *Open Forum Infect Dis* 2021;8 :ofab236.
- King LM, Lovegrove MC, Shehab N, *et al.* Trends in US outpatient antibiotic prescriptions during the coronavirus disease 2019 pandemic. *Clin Infect Dis* 2020:e652–e660.
- Hartnett KP, Kite-Powell A, DeVies J, *et al.* Impact of the COVID-19 pandemic on emergency department visits—United States, January 1, 2019–May 30, 2020. *Morb Mortal Wkly Rep* 2020;69:699–704.

7. Patel SY, Mehrotra A, Huskamp HA, Uscher-Pines L, Ganguli I, Barnett ML. Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. *JAMA Intern Med* 2021;181:388–391.
8. Mehrotra Ateev CM, Linetsky David, Hatch Hilary, Cutler David, Schneider Eric C. The impact of the COVID-19 pandemic on outpatient care: visits return to prepandemic levels, but not for all providers and patients. Commonwealth Fund website. <https://www.commonwealthfund.org/publications/2020/oct/impact-covid-19-pandemic-outpatient-care-visits-return-prepandemic-levels>. Published 2020. Accessed June 25, 2021.
9. Heist T SK, Butler S. Trends in overall and non-COVID-19 hospital admissions. Kaiser Family Foundation website. <https://www.kff.org/health-costs/issue-brief/trends-in-overall-and-non-covid-19-hospital-admissions/>. Published 2021. Accessed July 28, 2021.
10. The Premier healthcare database (COVID-19): data that informs and performs. Premier website. http://offers.premierinc.com/rs/381-NBB-525/images/PHD_COVID-19_White_Paper.pdf. Published April 10, 2020. Accessed May 31, 2021.
11. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;27:299–309.
12. Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating healthcare quality improvements. *Acad Pediatr* 2013;13 suppl 6:S38–S44.
13. Allegretti JR, Nije C, McClure E, et al. Prevalence and impact of *Clostridioides difficile* infection among hospitalized patients with coronavirus disease 2019. *JGH Open* 2021;5:622–625.
14. Gondi S, Beckman AL, Deveau N, et al. Personal protective equipment needs in the USA during the COVID-19 pandemic. *Lancet* 2020;395: e90–e91.
15. Hawes AM, Desai A, Patel PK. Did *Clostridioides difficile* testing and infection rates change during the COVID-19 pandemic? *Anaerobe* 2021;70: 102384.
16. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. Centers for Disease Control and Prevention website. <https://www.cdc.gov/hai/data/portal/progress-report.html>. Published 2021. Accessed November 10, 2021.
17. Baker MA, Sands KE, Huang SS, et al. The impact of COVID-19 on healthcare-associated infections. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*. 2021:ciab688.
18. Weiner-Lastinger LM, Pattabiraman V, Konnor RY, et al. The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: a summary of data reported to the National Healthcare Safety Network. *Infect Control Hosp Epidemiol* 2022;43:12–25.
19. Solanky D, Juang DK, Johns ST, Drobish IC, Mehta SR, Kumaraswamy M. Using diagnostic stewardship to reduce rates, healthcare expenditures and accurately identify cases of hospital-onset *Clostridioides difficile* infection. *Infect Control Hosp Epidemiol* 2021;42:51–56.
20. Kang M, Abeles SR, El-Kareh R, et al. The effect of *Clostridioides difficile* diagnostic stewardship interventions on the diagnosis of hospital-onset *C. difficile* infections. *Jt Comm J Qual Patient Saf* 2020;46:457–463.
21. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66(7):e1–e48.
22. Bunnell KL, Danziger LH, Johnson S. Economic barriers in the treatment of *Clostridium difficile* infection with oral vancomycin. *Open Forum Infect Dis* 2017;4:ofx078.
23. 2019 National and state healthcare-associated infections progress report. Centers for Disease Control and Prevention website. <https://www.cdc.gov/hai/data/portal/progress-report.html>. Published 2019. Accessed July 22, 2021.
24. Lewandowski K, Rosołowski M, Kaniewska M, et al. *Clostridioides difficile* infection in coronavirus disease 2019 (COVID-19): an underestimated problem? *Pol Arch Intern Med* 2021;131:121–127.
25. Premier healthcare database white paper: data that informs and performs. Premier Applied Sciences website. <https://learn.premierinc.com/white-papers/premier-healthcaredatabase-whitepaper>. Published 2020. Accessed April 21, 2022.